| Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine A Haghikia, S Jörg, A Duscha, J Berg, A Manzel, A Waschbisch, ... Immunity 43 (4), 817-829, 2015 | 845 | 2015 |
| Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study kappos | 619* | |
| TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis AP Gregory, CA Dendrou, KE Attfield, A Haghikia, DK Xifara, F Butter, ... Nature 488 (7412), 508-511, 2012 | 447 | 2012 |
| Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism A Duscha, B Gisevius, S Hirschberg, N Yissachar, GI Stangl, E Dawin, ... Cell 180 (6), 1067-1080. e16, 2020 | 421 | 2020 |
| Gut Microbiota–Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes A Haghikia, XS Li, TG Liman, N Bledau, D Schmidt, F Zimmermann, ... Arteriosclerosis, thrombosis, and vascular biology 38 (9), 2225-2235, 2018 | 271 | 2018 |
| Impacts of microbiome metabolites on immune regulation and autoimmunity S Haase, A Haghikia, N Wilck, DN Müller, RA Linker Immunology 154 (2), 230-238, 2018 | 223 | 2018 |
| Natalizumab use during the third trimester of pregnancy A Haghikia, A Langer-Gould, G Rellensmann, H Schneider, T Tenenbaum, ... JAMA neurology 71 (7), 891-895, 2014 | 219 | 2014 |
| Treatment of progressive multifocal leukoencephalopathy associated with natalizumab W Wenning, A Haghikia, J Laubenberger, DB Clifford, PF Behrens, ... New England Journal of Medicine 361 (11), 1075-1080, 2009 | 198 | 2009 |
| Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses K Hellwig, M Rockhoff, S Herbstritt, N Borisow, A Haghikia, B Elias-Hamp, ... JAMA neurology 72 (10), 1132-1138, 2015 | 183 | 2015 |
| Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study A Haghikia, A Haghikia, K Hellwig, A Baraniskin, A Holzmann, BF Décard, ... Neurology 79 (22), 2166-2170, 2012 | 181 | 2012 |
| Multiple sclerosis and pregnancy: experience from a nationwide database in Germany K Hellwig, A Haghikia, M Rockhoff, R Gold Therapeutic Advances in Neurological Disorders 5 (5), 247-253, 2012 | 169 | 2012 |
| Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment K Hellwig, A Haghikia, R Gold Multiple Sclerosis Journal 17 (8), 958-963, 2011 | 168 | 2011 |
| Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy RA Linker, A Haghikia Therapeutic advances in chronic disease 7 (4), 198-207, 2016 | 160 | 2016 |
| Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism A Haghikia, F Zimmermann, P Schumann, A Jasina, J Roessler, ... European Heart Journal 43 (6), 518-533, 2022 | 159 | 2022 |
| Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort AK Trampe, C Hemmelmann, A Stroet, A Haghikia, K Hellwig, H Wiendl, ... Neurology 78 (22), 1736-1742, 2012 | 155 | 2012 |
| Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin … A Haghikia, E Missol-Kolka, D Tsikas, L Venturini, S Brundiers, M Castoldi, ... European heart journal 32 (10), 1287-1297, 2011 | 150 | 2011 |
| Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry S Thiel, A Langer-Gould, M Rockhoff, A Haghikia, A Queisser-Wahrendorf, ... Multiple Sclerosis Journal 22 (6), 801-809, 2016 | 144 | 2016 |
| Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy B Stapel, M Kohlhaas, M Ricke-Hoch, A Haghikia, S Erschow, J Knuuti, ... European heart journal 38 (5), 349-361, 2017 | 139 | 2017 |
| PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease E Taherzadeh-Fard, C Saft, DA Akkad, S Wieczorek, A Haghikia, A Chan, ... Molecular neurodegeneration 6, 1-8, 2011 | 132 | 2011 |
| Therapies for multiple sclerosis: translational achievements and outstanding needs A Haghikia, R Hohlfeld, R Gold, L Fugger Trends in Molecular Medicine 19 (5), 309-319, 2013 | 128 | 2013 |
